Page last updated: 2024-12-06

bumadizone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bumadizone is a nonsteroidal anti-inflammatory drug (NSAID) that was previously used to treat inflammatory conditions such as rheumatoid arthritis. It was synthesized in the 1960s and was marketed under the brand name Butazolidin. Bumadizone is a potent inhibitor of cyclooxygenase (COX), the enzyme responsible for the production of prostaglandins, which are involved in inflammation and pain. However, due to its potential for serious side effects, including gastrointestinal bleeding, bone marrow suppression, and liver damage, bumadizone is no longer widely used. It has been replaced by newer NSAIDs that have a better safety profile. Despite its limited clinical use, bumadizone is still studied for its potential therapeutic effects in other conditions, such as cancer and Alzheimer's disease. Research into bumadizone's mechanisms of action and its potential applications in various diseases is ongoing.'

bumadizone: an anlgesic, antipyretic and anti-inflammatory agent; minor descriptor (75-86); on line & INDEX MEDICUS search MALONATES (75-86); RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bumadizone : A carbohydrazide obtained by formal condensation of one of the carboxy groups from butylmalonic acid with the hydrazino group of 1,2-diphenylhydrazine. Used (as its calcium semihydrate) for treatment of rheumatoid arthritis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID19161
CHEMBL ID2105456
CHEBI ID76119
SCHEMBL ID16438
MeSH IDM0263109

Synonyms (50)

Synonym
bumadizone
3583-64-0
2-[(1,2-diphenylhydrazino)carbonyl]hexanoic acid
einecs 222-710-1
bumadizona [inn-spanish]
butylmalonic acid mono(1,2-diphenylhydrazide)
bumadizone [inn:dcf]
n-butylmalonic acid n,n'-diphenylhydrazide
2-(2,3-diphenylcarbazoyl)hexansaeure
bumadizon
bumadizonum [inn-latin]
brn 0696638
b-64114
propanedioic acid, butyl-, mono(1,2-diphenylhydrazide)
b 64114
malonic acid, butyl-, mono(1,2-diphenylhydrazide)
bumadizone (inn)
D07264
2-[anilino(phenyl)carbamoyl]hexanoic acid
butylpropanedioic acid 1-(1,2-diphenyl hydrazide)
A26278
CHEMBL2105456
chebi:76119 ,
bumadizona
atd81g944m ,
bumadizonum
unii-atd81g944m
bumazidone
SCHEMBL16438
bumadizone [mi]
bumadizone [inn]
bumadizone [who-dd]
phenylbutazone impurity a [ep impurity]
butylmalonic acid n,n'-diphenylmonohydrazide
AC-22827
DTXSID0022698
AKOS025401613
2-(n,n'-diphenylhydrazinecarbonyl)hexanoic acid
(2rs)-2-[(1,2-diphenyldiazanyl)carbonyl]hexanoic acid
r heumatol
BCP24617
DB13286
Q851922
AMY10972
2-(anilinophenyl-carbamoyl)hexanoic acid
butylpropanedioic acid mono(1,2-diphenylhydrazide);bumadizone
CS-0009217
HY-17481
n-(2-carboxycaproyl)hydrazobenzene
EN300-18562821

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The proposed methods were successfully applied to the analysis of bumadizone either in bulk powder or in pharmaceutical formulation without interference from other dosage form additives, and the results were statistically compared with the established method."( Simultaneous HPTLC and RP-HPLC methods for determination of bumadizone in the presence of its alkaline-induced degradation product.
Abdelkawy, M; Ali, NW; Magdy, MA; ZaaZaa, HA, 2012
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
carbohydrazideA hydrazide consisting of hydrazine carrying one or more carboacyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.96 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]